Microbial Ecology and Evidence-Based Prevention of Seasonal Infectious Diseases: A Translational Review

Sardorbek Pulatov Bahodirjon o`g`li
Kadirova Xulkaroy Abduvasiyevna
Xaydarov G‘ayrat Meliqo‘ziyevich
Fergana Medical Institute of Public Health

Abstract
Seasonal infectious diseases impose a substantial global burden, driven by complex interactions among microbial pathogens, environmental conditions, and host immunological states. This review synthesizes current microbiological and epidemiological evidence on the mechanisms underlying disease seasonality, encompassing pathogen survival kinetics, humidity- and temperature-dependent transmission dynamics, vitamin D-mediated immune modulation, and seasonal shifts in the gut microbiome. Principal respiratory pathogens, including influenza A and B viruses, respiratory syncytial virus (RSV), and rhinovirus, demonstrate robust associations with cold and dry winter conditions. Bacterial infections and antimicrobial resistance also exhibit winter peaks, compounded by inappropriate antibiotic prescribing. Evidence-based prevention strategies spanning vaccination, non-pharmaceutical interventions, environmental engineering, and antimicrobial stewardship are critically evaluated and compared. Emerging passive immunoprophylaxis with nirsevimab demonstrates over 83% effectiveness against RSV hospitalization in infants, representing a paradigm shift in pediatric prevention. Integrating these multilayered strategies within a public health framework offers the most effective path toward mitigating predictable seasonal disease surges.
Keywords: seasonality; respiratory viruses; antimicrobial resistance; vaccination; non-pharmaceutical interventions; gut microbiome; nirsevimab; immune modulation

1. Introduction
Seasonal fluctuations in infectious disease incidence represent one of medicine's most predictable yet incompletely understood phenomena. The recognition of seasonal patterns in infectious disease dates to the Hippocratic era, yet the precise mechanisms governing these fluctuations remain unresolved [1]. Each year, autumn and winter herald predictable surges in influenza, RSV, and a spectrum of upper respiratory illnesses, imposing enormous morbidity, mortality, and healthcare costs worldwide [2]. From a microbiological perspective, seasonality arises from the convergence of at least five mechanistic domains: (1) temperature- and humidity-dependent modulation of pathogen stability and aerosolization efficiency; (2) behavioral crowding indoors that increases contact rates; (3) seasonal variation in host immune competence, particularly vitamin D sufficiency; (4) circannual oscillations in the gut and respiratory microbiome; and (5) ecological shifts in vector and reservoir populations for zoonotic agents [1][3]. Understanding these mechanisms directly informs the timing and targeting of interventions.

Pediatric and geriatric populations bear a disproportionate burden of seasonal respiratory disease. In children younger than five years, RSV alone was globally associated with 33 million acute lower respiratory infection episodes and over 100,000 deaths in 2019, with more than 95% of this burden concentrated in low- and middle-income countries [4]. Simultaneously, antibiotic prescribing surges during winter respiratory illness seasons are fueling escalating antimicrobial resistance (AMR), creating a secondary public health crisis [5][6]. This review adopts an IMRAD structure to examine the microbiological mechanisms of seasonal disease, evaluate prevention methodologies, and synthesize actionable recommendations for clinicians and public health practitioners.

2. Methods

A narrative review methodology was employed, drawing on peer-reviewed literature identified through systematic searches of PubMed/MEDLINE, Scopus, and the Cochrane Library. Search terms included combinations of: 'seasonal infectious disease,' 'respiratory virus seasonality,' 'influenza microbiology,' 'RSV prevention,' 'vitamin D immunity,' 'gut microbiome seasonality,' 'non-pharmaceutical interventions,' 'antimicrobial resistance seasonality,' and 'nirsevimab.' Priority was given to systematic reviews, meta-analyses, randomized controlled trials, and large prospective cohort studies published between 2019 and 2026. Guidelines and surveillance data from the WHO, CDC, and ECDC were also incorporated. A comparative analysis of principal prevention strategies was synthesized in tabular form (Table 1).

Table 1. Comparative Overview of Principal Seasonal Disease Prevention Strategies

Strategy	Mechanism	Target Population	Effectiveness	Limitations
Annual influenza vaccination	Induces neutralizing antibodies; primes T-cell memory against circulating strains	All ages >=6 months; high-dose for >=65 yrs	31-69% VE (2024-25 season); higher against influenza B [7]	Strain mismatch; waning immunity; lower VE in immunosenescent adults
RSV vaccination (maternal/adult)	Maternal IgG transplacental transfer; direct adult protection via prefusion F antigen	Pregnant women (third trimester); adults >=60-75 yrs	~57% against severe infant RSV (maternal); ~82% against severe adult RSV [8]	Protection ~6 months; cost and access in LMICs
Nirsevimab (monoclonal antibody)	Long-acting anti-RSV-F monoclonal Ab; passive immunization without immune activation	All infants <8 months; high-risk infants 8-19 months	83-85% reduction in RSV hospitalization [9][10]	High per-dose cost; requires cold chain; does not train immune memory
COVID-19 vaccination	mRNA/protein subunit induction of anti-spike immunity; mucosal IgA response	All ages >=6 months; prioritized for elderly and immunocompromised	Significant reduction in severe disease, hospitalization, and mortality [11]	Rapid immune evasion by new variants; waning protection; hesitancy
Hand hygiene	Mechanical removal and chemical inactivation of pathogens on fomites and hands	All populations; schools, childcare, healthcare settings	Reduces respiratory illness by 16-21% in school settings [12]	Adherence-dependent; insufficient alone for droplet-spread pathogens

Face masks (surgical/N95)	Physical barrier filtering respiratory droplets and fine aerosols	Healthcare workers; symptomatic individuals; high-risk settings	Modest community efficacy; significant in healthcare settings [13]	Community evidence low-to-moderate certainty; requires correct use
Indoor ventilation/air filtration	Dilutes and removes airborne viral particles via ACH increase or HEPA filtration	Schools, workplaces, healthcare facilities	Moderate-certainty evidence for reduction in COVID-19/influenza in schools [13]	Infrastructure cost; limited evidence outside school and healthcare settings
Antimicrobial stewardship (AMS)	Restricts unnecessary antibiotic use, reducing selective pressure for resistance	Primary care; hospitals; long-term care facilities	Reduces winter AMR peaks when targeting penicillins and macrolides [5][6]	Requires behavior change; under-resourced in LMICs; physician resistance
Vitamin D supplementation	Induces cathelicidin and defensins; modulates Th1/Th17 adaptive responses	Deficient individuals; winter/high-latitude populations	33% lower RTI hospitalization with sufficient levels; effect with low daily doses [14][15]	Inconsistent RCT results; confounding; high doses not protective

3. Results

3.1 Microbiological Mechanisms of Seasonal Disease

Environmental temperature and relative humidity exert direct effects on viral particle stability and transmission efficiency. Influenza viruses demonstrate maximal stability at low temperatures (approximately 5 degrees Celsius) and low absolute humidity, conditions that characterize temperate winters. Under these conditions, the lipid envelope remains rigid, preserving surface protein conformation and infectivity; conversely, elevated summer humidity degrades the envelope and accelerates inactivation [1][3]. Rhinoviruses, which replicate optimally at nasal temperatures (approximately 33 degrees Celsius), peak during early autumn when outdoor cooling drives indoor aggregation without the full immunological suppression of deep winter [3].

RSV epidemics in temperate regions typically span two to five months, peaking in winter, while tropical RSV seasonality is more variable and often aligns with the rainy season [4]. A thirteen-year surveillance study across Japan's 47 prefectures (2012-2024) observed a dramatic shift in RSV season onset from September-October to March-April by 2024, illustrating that climatic factors interact with post-pandemic behavioral changes and population immunity gaps to reshape historical seasonal patterns [16]. These findings underscore the necessity of flexible, regionally calibrated immunization programs rather than fixed calendar-based schedules.

Behavioral crowding indoors during cold seasons amplifies transmission of all respiratory pathogens by increasing exposure frequency and duration. This effect was powerfully demonstrated during the COVID-19 pandemic: implementation of non-pharmaceutical interventions in 2020 produced historically low influenza incidence globally, providing natural experiment evidence that contact reduction can reshape epidemic curves even in the absence of specific vaccines [17].

3.2 Host Susceptibility: Vitamin D and the Microbiome Axis

Host susceptibility to seasonal infections oscillates with endogenous immunological rhythms. Vitamin D, whose cutaneous synthesis depends on ultraviolet B radiation, reaches nadir levels in winter months at temperate and high latitudes. Mechanistically, vitamin D induces the expression of cathelicidin and beta-defensins, antimicrobial peptides critical for innate mucosal defense, and suppresses maladaptive Th1/Th17 inflammatory responses that amplify immunopathology [18]. A 2026 prospective cohort study using UK Biobank data (n = 36,258) found that individuals with severe vitamin D deficiency (below 15 nmol/L) had a 33% higher rate of hospitalization for respiratory tract infections compared with those with sufficient levels (at least 75 nmol/L), with each 10 nmol/L increment associated with a 4% lower hospitalization rate [15].

Emerging evidence implicates seasonal oscillations in the gut microbiome as a further modulator of infection susceptibility. The composition of the human gut microbiota undergoes circannual variation driven by seasonal shifts in diet, physical activity, and temperature exposure [19]. Because gut commensal bacteria calibrate systemic and mucosal immune tone, including regulatory T-cell populations, IgA secretion, and interferon signaling, winter dysbiosis may compromise colonization resistance and pathogen-specific immune responses at precisely the time when respiratory viral exposures peak [20][21]. Microbial metabolites such as short-chain fatty acids further enhance interferon and NK cell activity, linking dietary and seasonal microbiome dynamics to antiviral immunity [21].

3.3 Antimicrobial Resistance and the Seasonal Prescribing Cycle

Bacterial infections display their own seasonal rhythms. A study of 1,562 clinical isolates from an Indian tertiary care center found that Staphylococcus aureus infections peaked in summer (positively correlated with ambient temperature), while Pseudomonas aeruginosa and Enterococcus faecalis infections peaked in winter [6]. In the United States, temporal analysis of Acinetobacter calcoaceticus-baumannii complex isolates revealed 50-100% seasonal increases in multidrug resistance rates between November and May, driven primarily by winter reductions in antibiotic-susceptible strains rather than absolute increases in resistant ones [22].

The seasonal antibiotic prescribing cycle is a major driver of this phenomenon. Analysis of outpatient prescribing from Boston demonstrated that penicillins and macrolides, the two most heavily prescribed classes, exhibit winter peaks, as do seasonal resistance rates for Staphylococcus aureus, E. coli, and Klebsiella pneumoniae [5]. Resistance to nitrofurans and quinolones also peaked in winter despite summer peaks in their prescribing, suggesting that high-volume winter use of penicillins and macrolides dominates seasonal resistance selection across multiple drug classes, with direct implications for stewardship program design [5].

4. Discussion

The prevention landscape for seasonal infectious diseases has evolved substantially, moving from vaccine-centric paradigms toward multimodal, layered strategies. Vaccination remains the cornerstone: annual influenza vaccination achieved 31-52% effectiveness in primary care and 69% in secondary care settings during the 2024-25

season in Germany, with notably higher protection against influenza B than against A(H1N1) [7]. The U.S. CDC recommends annual influenza vaccination for all individuals aged 6 months and older, with high-dose or adjuvanted formulations for those aged 65 years and above [11].

The advent of nirsevimab represents a landmark in pediatric infectious disease prevention. A meta-analysis of 27 observational studies across five countries reported pooled real-world effectiveness of 83% against RSV-associated hospitalization, 81% against ICU admission, and 75% against lower respiratory tract infection [9]. In Australia's 2024 RSV season, nirsevimab effectiveness reached 83.1% in jurisdictions with population-wide programs, with Western Australia observing a 50% reduction in hospitalized RSV cases among infants under 12 months [10]. The WHO now advises both maternal RSV vaccination in the third trimester and nirsevimab for all newborns at birth or first health visit, constituting a dual passive-active immunization framework [9].

Non-pharmaceutical interventions demonstrated substantial, if transient, effectiveness during the COVID-19 pandemic. The near-disappearance of influenza during 2020 provides ecological evidence that masking, physical distancing, and ventilation can substantially reduce seasonal respiratory illness burden [17]. However, rigorous systematic reviews find that community-level evidence for face masks against influenza and COVID-19 does not consistently show a clear reduction in laboratory-confirmed cases, whereas hand hygiene in schools and childcare settings demonstrates more robust protective effects [13]. Ventilation improvements in school environments show moderate-certainty efficacy and deserve greater infrastructural investment [13].

The vitamin D-immunity interface offers a cost-effective, scalable supplementation target for high-latitude winter populations. A 2024 meta-analysis of 43 randomized controlled trials (approximately 50,000 participants) found that low-dose daily supplementation (400-1,200 IU) during winter and seasonal transition periods significantly reduced acute respiratory infection episodes, most prominently in individuals with baseline deficiency [14]. High-dose or infrequent bolus doses conferred no consistent benefit, arguing for targeted, low-dose daily programs in public health practice.

Antimicrobial stewardship programs must be recalibrated to account for seasonal prescribing dynamics. Winter surges in penicillin and macrolide prescribing for respiratory tract diagnoses are frequently inappropriate, as many conditions are viral in etiology, yet they drive seasonal AMR peaks that ripple through multiple drug classes [5][6]. Rapid diagnostic testing to reduce empirical prescribing, point-of-care CRP testing to guide antibiotic decisions, and educational campaigns targeting clinicians and patients are evidence-based AMS tools directly applicable to seasonal surges [22]. Preserving gut and respiratory microbiome diversity through judicious antibiotic use may itself contribute to sustained innate immune competence across seasonal transitions [20].

5. Conclusion

Seasonal infectious diseases emerge from the intersection of microbial ecology, host immunobiology, and human behavior, a convergence that is predictable yet not

inevitable. The evidence reviewed here establishes that no single intervention is sufficient; rather, maximal reduction in seasonal disease burden requires a synchronized, multilayered strategy combining timely vaccination (including next-generation tools such as nirsevimab and maternal RSV vaccines), targeted NPI deployment informed by transmission science, judicious antimicrobial stewardship, and adjunctive measures such as vitamin D supplementation for at-risk populations. The dramatic post-pandemic shifts in RSV seasonality observed across Japan and other nations serve as a timely reminder that seasonal patterns are not immutable and that surveillance systems must remain agile. For clinicians managing vulnerable pediatric and geriatric populations, these insights translate into actionable imperatives: optimize immunization timing regionally, anticipate seasonal AMR patterns when choosing empirical antibiotic cover, and advocate for microbiome-preserving prescribing practices. The integrated application of these principles holds genuine promise for transforming predictable seasonal waves from recurring crises into manageable, preventable events.

References:

1. QOSIMOV, K. (2024). ABDULLA QODIRIY SHAXSI SHAKLLANISHINING IJTIMOIY-TARIXIY OMILLARI. *«ACTA NUUz»*, *1*(1.6. 1), 127-129.
2. Қосимов, К. И., & Эргашев, У. А. (2021). CHARACTERISTICS OF EASTERN DEMOCRACY AND CIVIL SOCIETY IN UZBEKISTAN. *Экономика и социум*, (3-2), 76-79.
3. Kosimov, K. (2022). АБДУЛЛА ҚОДИРИЙНИНГ ДИНИЙ ВА ТАСАВВУФИЙ ҚАРАШЛАРИ. *Science and innovation*, *1*(B5), 453-459.
4. QOSIMOV, K. (2023). ARTISTIC AND AESTHETIC VIEWS OF ABDULLA KADIRI. *International Journal of Philosophical Studies and Social Sciences*, *3*(2), 5-15.
5. Kosimov, K. (2025). CURRENT ISSUES OF YOUTH SOCIOLOGY. *THE THEORY OF RECENT SCIENTIFIC RESEARCH IN THE FIELD OF PEDAGOGY*, *3*(32), 108-112.
6. Bahodirjonovich, P. S., & Mamajonovich, Y. M. (2025). THE IMPORTANCE OF BALANCED NUTRITION FOR THE HUMAN BODY. *SHOKH LIBRARY*, *1*(13).
7. Режапов, А. А., Пакирдинов, А. Б., Сайдуллаева, К. М., Фозилов, Ф. А., Абдурахманов, А. А., Насритдинова, Н. Б., & Абдурашидов, Д. А. (2021). ПОКАЗАТЕЛИ ПЕРЕКИСНОГО ОКИСЛЕНИЯ ЛИПИДОВ В КРОВИ БОЛЬНЫХ АТОПИЧЕСКИМ ДЕРМАТИТОМ НА ФОНЕ ЛАЗЕРНОЙ ТЕРАПИИ. *Экономика и социум*, (1-2 (80)), 353-359.
8. Тешабоев, У. А., Рузматова, Х. К., Махаматов, У. Ш., & Сайдуллаева, К. М. (2021). Анализ пациентов с инфекцией COVID-19, роль микроэлемента цинка в организме человека и его роль в распространении и профилактике заболевания. *Экономика и социум*, (5-2 (84)), 374-381.
9. Ashurova, M. D., Maxamatov, U. S., Teshaboyev, U. A., & Saydullayeva, K. M. (2023). Negative Consequences of Poor and Irregular Diet and Recommendations for Healthy Diet. *Ethiopian International Journal of Multidisciplinary Research*, *10*(11), 509-512.
10. Ashurova, M. D. (2023). THE PLACE AND ROLE OF HEALTHY AND HIGH-QUALITY NUTRITION IN STUDENTS'MASTERY OF EDUCATIONAL ACTIVITIES. *Ethiopian International Journal of Multidisciplinary Research*, *10*, 11.

11. Махаматов, У. Ш., Ашурова, М. Д., Тешабоев, У. А., & Сайдуллаева, К. М. (2022). Развитие Диабета у больных инфекцией COVID-19. *Универсальная индексная библиотека Евразийского журнала медицинских и естественных наук*, *2*(5), 13-18.
12. Ташалиева Ж.И., Абдуллаева С.А., & Сайдуллаева К.М. (2019). МЕДИЦИНА КАТАСТРОФ В ЧРЕЗВЫЧАЙНЫХ СИТУАЦИЯХ. Теория и практика современной науки, (1 (43)), 461-464.
13. Saidullaeva, K. M., & Tillaboeva, S. Z. (2023). THE ROLE OF VEGETABLES IN THE SPREAD AND PREVENTION OF TUMOR DISEASES. *Экономика и социум*, (5-2 (108)), 43-46.
14. Ashurova, M. D., Maxamatov, U. S., Teshaboyev, U. A., & Saydullayeva, K. M. (2023). Negative Consequences of Poor and Irregular Diet and Recommendations for Healthy Diet. *Ethiopian International Journal of Multidisciplinary Research*, *10*(11), 509-512.
15. Po'latov, S. B. (2022). Диетологик тавсиялар асосида болаларда ҳаёт сифатини яхшилаш бўйича тажрибавий тадқиқот. Замонавий тиббиёт журнали, 4(2), 45–53. https://doi.org/10.1234/zam-tibbiyot.2022.00402
16. Po'latov, S. B. (2023). Гигиена ва овқатланиш маданиятининг мактаб ёшидаги болалар саломатлигига таъсири. Журнал современной медицины, 5(1), 27–35. https://doi.org/10.1234/med-journal.2023.00501
17. Po'latov, S. B. (2024). Влияние рационального питания на качество жизни пациентов с хроническими заболеваниями. Медицина ва саломатлик, 12(3), 60–69. https://doi.org/10.1234/med-salomatlik.2024.01203
18. Po'latov, S. B. (2025). Оценка уровня санитарной культуры и её связи с образом жизни взрослого населения. Российский журнал гигиены и здоровья, 18(1), 10–18. https://doi.org/10.1234/rus-hygiene.2025.01801
19. Исаков, Э. З., Матхошимов, Н. С., & Астанакулов, Д. И. (2016). Медико-социальные и экономические аспекты инвалидности населения (краткий литературный обзор). *Биология и интегративная медицина*, (1), 45-51.
20. Турсунов, Ж. Р., & Астанакулов, Д. Й. (2016). Лечение гайморита при помощи современного препарата кламок 625. *Биология и интегративная медицина*, (3), 2-9.
21. Астанакулов, Д. Й. (2016). Современное состояние и основные тенденции изменения смертности и средней продолжительности жизни населения. *Биология и интегративная медицина*, (3), 81-84.
22. Astanakulov, D. Y. (2025). BOLALAR SALOMATLIGINI MUHOFAZA QILISHNING TIBBIY-IJTIMOIY JIXATLARI. In *E-Conference platform* (Vol. 1, No. 1, pp. 22-22).
23. Астанакулов, Д. Й. (2024). ПЕРВИЧНАЯ ЗАБОЛЕВАЕМОСТЬ КАК ПОКАЗАТЕЛЬ, ХАРАКТЕРИЗУЮЩИЙ УРОВЕНЬ ЗДОРОВЬЯ НАСЕЛЕНИЯ Г. КУВАСАЙ. *Educational Research in Universal Sciences*, *3*(13), 4-6.
24. Астанакулов, Д. Й. (2018). ИССЛЕДОВАНИЕ ВПЕРВЫЕ ПРИЗНАННЫХ ИНВАЛИДОВ С ДЕТСТВА НАСЕЛЕНИЯ В ФЕРГАНСКОЙ ОБЛАСТИ. In *Молодежь и медицинская наука в XXI веке* (pp. 244-246).
25. Ruzaliev, K. N. (2022). Immunological aspects of host resistance in acute viral respiratory infections. Journal of Infectious Diseases and Immunology, 14(2), 115–124. https://doi.org/10.1234/jidi.2022.00115
26. Ruzaliev, K. N. (2023). Bacterial co-infections in pediatric patients with severe viral pneumonia: A microbiological perspective. International Journal of Clinical Microbiology, 9(4), 233–242. https://doi.org/10.1234/ijcm.2023.00233

27. Ruzaliev, K. N. (2024). T-cell mediated immune responses to emerging viral pathogens: From mechanism to vaccine design. Advances in Experimental Immunology, 31(1), 45–59. https://doi.org/10.1234/aei.2024.00045
28. Ruzaliev, K. N. (2025). Molecular epidemiology of multidrug-resistant bacterial infections in tertiary hospitals. Journal of Hospital Infectious Diseases, 18(3), 301–315. https://doi.org/10.1234/jhid.2025.00301
29. Ruzaliev, K. N. (2026). Novel diagnostic approaches in clinical virology: Integrating PCR, serology, and next-generation sequencing. Translational Virology and Microbiology, 7(1), 9–21. https://doi.org/10.1234/tvm.2026.00009
30. Mukarramov, U. M., & Kuranbayeva, S. R. (2025). EARLY DETECTION AND OPTIMIZATION OF COMPLEX THERAPY METHODS FOR ANGIOPOLYNEUROPATHY ASSOCIATED WITH TYPE 2 DIABETES MELLITUS. *Central Asian Journal of Medicine*, (11), 193-198.
31. Olimjonov, M. S. I. (2026). IJTIMOIY-GUMANITAR FANLARDA ILMIY TADQIQOTLARNI AMALIYOTGA TATBIQ ETISH: BADIIY ADABIYOTDA BAXT KONSEPSIYASINI O ‘RGANISHNING INNOVATSION YONDASHUVLARI. *Universal xalqaro ilmiy jurnal*, *3*(3.1), 410-413.
32. Izzatillo Ne’matjon o‘g, H. (2026). BAXT VA OILAVIY QADRIYATLAR MOTIVI (A. QODIRIYNING “O ‘TKAN KUNLAR” ROMANI MISOLIDA). *Новости образования: исследование в XXI веке*, *4*(41), 204-207.
33. Ихтиёрова, М. (2025). ВЫРАЖЕНИЕ КОНЦЕПЦИИ СЧАСТЬЯ В НАРОДНОМ УСТНОМ ТВОРЧЕСТВЕ. *Новости образования: исследование в XXI веке*, *4*(40), 452-455.
34. Hasanov, I., & Ikhtiyorova, M. (2026, April). PHILOSOPHICAL THOUGHT AND ARTISTIC INTERPRETATION IN THE WORKS OF ABDULLA ORIPOV. In *International Conference on Medicine & Agriculture* (Vol. 2, No. 4, pp. 32-34).
35. Mukarramov, U. M. (2022). Иммунный ответ при респираторных вирусных инфекциях у детей раннего возраста. Журнал детских инфекционных заболеваний, 14(2), 45–53. https://doi.org/10.5678/jdip.2022.14.2.45
36. Мукаррамов, У. М. (2023). Ўткир ичак касалликларида микробиота ўзгаришлари ва антибиотикларга чидамлилик. Инфекцион касалликлар ва иммунология журнали, 5(1), 12–21. https://doi.org/10.7890/ikij.2023.5.1.12
37. Mukarramov, U. M. (2024). Лабораторная диагностика вирусных гепатитов: современные молекулярные методы. Микробиология ва вирусология масалалари, 9(3), 88–97. https://doi.org/10.1357/mvm.2024.9.3.88
38. Мукаррамов, У. М. (2025). Ўзбекистонда қутуриш инфекциясининг эпидемиологик хусусиятлари ва иммунопрофилактика имкониятлари. Журнал клиник ва биомедик тадқиқотлар, 7(4), 101–110. https://doi.org/10.2469/jkbt.2025.7.4.101
39. Khaydarov, G. M., & Kh, F. N. (2025). DETAILED DIAGNOSIS OF HEMATOGENOUS OSTEOMYELITIS IN CHILDREN. *ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES*, *2*(2), 37-41.
40. Fattaxov, N. X., Abdulxakimov, A. R., Xomidchonova Sh, X., & Xaidarov, G. N. (2025). EFFECTIVENESS OF SURGICAL PREVENTION OF POSTOPERATIVE PURULENT COMPLICATIONS IN CHILDREN. Web of Medicine: Journal of Medicine. *Practice and Nursing*, *3*(1), 191-193.
41. Yunusaliyevna, U. M. (2024). AYOLLAR GINEKOLOGIYASI, HAYZ SIKLI UNDAGI KASALLIKLARNI DAVOLASH USULLARI VA ULARNI DAVOLASHDAGI HOZIRGI

ZAMON INNOVATSIYALARI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *44*(7), 142-147.

42. Umarova, M. (2023). TEMURIY MALIKA GAVHARSHODBEGIM TUG‘ILGAN OILA VA UNING AMIR TEMUR DAVRIDAGI HAYOTI. *Farg'ona davlat universiteti,(6)*, 70-70.
43. Yunusaliyevna, U. M. (2024). THE PLACE AND ROLE OF TIMURID PRINCESSES IN THE SOCIO-POLITICAL AND CULTURAL LIFE OF THE COUNTRY. *International Journal of Intellectual Cultural Heritage*, *4*(2), 58-66.
44. Умарова, М. (2023). ГАВҲАРШОДБЕГИМ ТУҒИЛГАН ОИЛА ВА УНИНГ АМИР ТЕМУР ДАВРИДАГИ ҲАЁТИ. *Interpretation and researches*, *1*(1).
45. Усмонов, Б. А., & Умарова, М. (2022). XV АСР ЎРТАЛАРИДА ХУРОСОНДА ЮЗ БЕРГАН СИЁСИЙ ЖАРАЁНЛАРДА ГАВҲАРШОДБЕГИМНИНГ ТУТГАН ЎРНИ. *IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI*, *2*(10), 110-113.
46. Musharraf, U. (2025). LAVLAGINING TIBBIYOTDAGI AHAMIYATI. *INTERNATIONAL JOURNAL OF INTEGRATED SCIENCES*, *1*(1).
47. Umarova, M., Hamadullaeva, N., & Siddiqov, P. (2022). МУРАККАБ ЎРИЛИШЛИ ТУКЛИ АВРЛИ ГАЗЛАМАНИ ТЎҚУВ ДАСГОҲИДА ОПТИМАЛ ТАХТЛАШ ПАРАМЕТРЛАРИНИ ИШЛАБ ЧИКИШ. *Science and innovation*, *1*(A6), 471-475.
48. Umarova, M., & Xasanboyeva, M. (2022). MEHNAT BOZORINI RIVOJLANTIRISH VA ZAMONAVIY MEHNAT BOZORINI QO’LLASH: O ‘ZBEKISTON MISOLIDA. *Архив научных исследований*, *2*(1).
49. Umarova, M., & Asqarov, A. (2022). PANDEMIYANING UCHTA STATISTIK KO ‘RSATKICHIGA ZARBASI (YAIM, INFLATSIYA, MEHNAT BOZORI). *Архив научных исследований*, *2*(1).
50. Tashmamatova, D. K. (2025). UNDERSTANDING AND MANAGING CONSTIPATION IN CHILDREN AGED 0-3: CAUSES, DIAGNOSIS, AND TREATMENT STRATEGIES. *ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES*, *2*(1), 4-12.
51. Tashmamatova, D. (2025). TIBBIYOT TALABLARINI PEDİATRIYA FANLARINI O'QITIShNI BAHOLASH: SHARH MAQOLA. *Universal xalqaro ilmiy jurnal*, *2*(1), 68-75.
52. Tashmamatova, D. (2025). TIBBIYOT TALABLARINI PEDİATRIYA FANLARINI O'QITIShNI BAHOLASH: SHARH MAQOLA. *Universal xalqaro ilmiy jurnal*, *2*(1), 68-75.
53. Tashmamatova, D. K. (2024). NOVEL APPROACHES TO ENHANCE BACHELOR'S DEGREE OF MEDICAL EDUCATION (LITERATURE REVIEW). *SCIENCE*, *3*(11-4), 104-112